Quarterly Management Statement for the Period Ending March 31, 2016

Quarterly Management Statement for the Period Ending March 31, 2016

Phase II strategy for MP0250 laid-out, strategy about immuno-oncology pipeline disclosed, business and financial outlook 2016 fully confirmed

R&D and Operating Highlights:

  • Proprietary oncology pipeline progressing with phase II development plan for lead asset MP0250 in multiple myeloma disclosed
  • Concept for immuno-oncology pipeline and two early-stage programs announced:
    a VEGF/ PD-1 multi-DARPin and tumor-localized agonists
  • Abicipar advances in phase III trials, as strategic partner Allergan reiterated its firm commitment to DARPins

Financial Highlights:

  • Ongoing strong financial position with CHF 205.9 million cash balance (including short-term time deposits) as of March 31, 2016, down CHF 9.5 million versus December 31, 2015, and up 13% year-over-year
  • Net cash used from operating activities of CHF 7.2 million, up CHF 3.4 million year-on-year, reflecting ongoing scale-up of R&D, operational activities and the company’s pipeline
  • Operating loss of CHF 2.2 million and net loss of CHF 4.2 million in the first quarter 2016
  • Growing talent base with 94 full-time employees as of March 31, 2016, up 25% year-over-year and an increase of 5% compared to year-end 2015

Zurich-Schlieren, April 28, 2016. Molecular Partners AG (ticker: MOLN), a clinical-stage biopharmaceutical company that is developing a new class of therapies known as DARPins, today provided its Quarterly Management Statement and key financial highlights for the period ending March 31, 2016.

“We are very pleased with the development and further fortification of our broad and novel pipeline, the renewed commitment of our strategic partners to our innovative DARPin technology platform, as well as the continued strength of our financial position during the first quarter,” said Dr. Christian Zahnd, Chief Executive Officer of Molecular Partners. “We look forward to continue to focus on the remainder of 2016 with several additional milestones expected, including clinical milestones.”

Business highlights in the first quarter 2016

Proprietary oncology pipeline progressing with the phase II development plan for lead asset MP0250 in multiple myeloma disclosed

In the first quarter of 2016, Molecular Partners provided guidance on the Phase II development strategy for MP0250, the lead oncology DARPin. The company will initiate the first Phase II study of this compound in the second half of 2016 in patients with multiple myeloma. The study will investigate MP0250 in combination with bortezomib and dexamethasone in patients whose cancers became refractory while on bortezomib therapy, and who have received at least two prior regimens including bortezomib and an immunomodulatory drug.

Beyond MP0250, Molecular Partners is advancing a growing proprietary pipeline of DARPin therapies. The pipeline includes MP0274, a multi-DARPin that targets HER2, providing broad blockade of HER1, HER2 and HER3-mediated signaling and inducing apoptosis (programmed cell death) in HER2-overexpressing cells. MP0274 is currently in preclinical development.

Concepts for immuno-oncology pipeline and two early-stage programs announced

In March 2016, the company announced its strategy in immuno-oncology, including the disclosure of two multi-DARPin programs. The first program targets the validated immune checkpoint PD-1 as well as VEGF-A, aiming to enhance PD-1 efficacy. The second program is designed to potently activate T-cells in the tumor only without activating circulating T-cells, thus circumventing systemic toxicities.

Immuno-oncology is a revolutionary approach to anti-cancer treatment that redirects the body’s immune system to fight cancer cells. Investigators are studying many different ways to modulate immune checkpoints used by the body to regulate the immune system. While many of these clinical studies are yielding promising results, novel approaches are needed.

Abicipar advances in phase III trials, reiterated commitment of strategic partner Allergan

Molecular Partners is pleased to see abicipar advancing in its Phase III trials in wet AMD which started in July 2015. The company remains confident to see further development of this product candidate in additional indications such as diabetic macular edema (DME) as well as progress of other DARPins in the ophthalmology alliance with Allergan, which also includes an earlier stage VEGF/PDGF multi-DARPin in wet AMD. In the context of the withdrawn merger of Allergan with Pfizer, Allergan management publicly stated on April 6, 2016, that abicipar “continues to progress in clinical development and could be a true game changer for people suffering with this disease by lowering the injection burden significantly.”

Financial Highlights in 1Q 2016: Financial development as expected, ongoing strong position

In the first quarter of 2016, Molecular Partners recognized total revenues of CHF 6.8 million (1Q 2015: CHF 5.8 million) and incurred total expenses of CHF 9.0 million (1Q 2015: CHF 6.2 million). This led to an operating loss of CHF 2.2 million for the quarter (1Q 2015: operating loss of CHF 0.4 million). The company recognized net financing expenses of CHF 2.0 million (1Q 2015: net financing expenses of CHF 2.0 million), mainly driven by negative FX effects on USD and EUR cash positions. This resulted in a net loss of CHF 4.2 million for the first quarter 2016 (1Q 2015: net loss of CHF 2.4 million).

The net cash used from operating activities during the first quarter 2016 was CHF 7.2 million (1Q 2015: net cash used from operating activities of CHF 3.8 million). Including the time deposits, the cash and cash equivalents position of the company decreased by CHF 9.5 million versus year-end 2015 to CHF 205.9 million as of March 31, 2016 (December 31, 2015: CHF 215.4 million). The total shareholders’ equity position decreased by CHF 4.8 million to CHF 147.0 million as of March 31, 2016 (December 31, 2015: CHF 151.8 million).

As of March 31, 2016, the company employed 94 FTEs, more than 90% of whom are employed in R&D functions (December 31, 2015: 89 FTEs; March 31, 2015: 75 FTEs).

Key figures as of March 31, 2016

Key Financials (unaudited)
(CHF million, except per share, FTE data)

1Q 2016

1Q 2015

change

Total revenues

6.8

5.8

1.0

R&D expenses

-7.5

-4.6

-2.9

G&A expenses

-1.5

-1.6

0.1

Operating loss

-2.2

-0.4

-1.8

Net loss

-4.2

-2.4

-1.8

Basic net loss per share (in CHF)

-0.21

-0.13

-0.08

Net cash from (used in) operating activities

-7.2

-3.8

-3.4

Cash & cash equivalents as of March 31

196.3

182.3

14.0

Cash balance (incl. time deposits) as of March 31

205.9

182.3

23.6

Total shareholders’ equity as of March 31

147.0

146.5

0.5

Number of total FTE as of March 31

93.7

74.8

18.9

– thereof in R&D

85.5

67.9

17.6

– thereof in G&A

8.2

6.9

1.3

“In the first quarter of 2016, Molecular Partners’ financial position developed fully in line with our projections and expectations amid the substantial scale-up of our R&D and operational activities,” said Andreas Emmenegger, Chief Financial Officer of Molecular Partners. “We reiterate our previously provided financial guidance for 2016.”

Successful placement of shares

After the end of the first quarter, on April 13, 2016, employees, consultants, members of the board of directors of the company as well as certain venture capital shareholders successfully placed 1.1 million shares in an accelerated bookbuilding transaction at a price of CHF 27.50 per share. This share placement was done in order to provide employees, consultants and members of the board of directors the necessary funds to pay taxes and social securities resulting from the exercise of stock options which were approaching expiration. Following the option exercise and transaction, the executive management team holds an increased position of Molecular Partners’ shares compared to the situation before the share placement.

Business outlook and priorities

With the announcement of the share placement transaction on April 13, 2016, Molecular Partners AG fully confirmed its outlook and priorities for the financial year 2016.

In ophthalmology, the company will remain focused on supporting its partner Allergan in progressing abicipar through Phase III trials in wet AMD, and possibly in initiating Phase III trials for abicipar in DME.

In oncology, Molecular Partners AG reiterated during the first quarter 2016 its commitment to conduct a Phase II trial of MP0250 in the treatment of multiple myeloma (MM) in combination with bortezomib and dexamethasone, and continues to expect the enrolment of the first patient in the second half of 2016. The company’s management team also remains committed to advancing MP0274 into clinical development in 2016, and plans to initiate a Phase I trial of MP0274 by the end of the year.

On March 7, 2016, Molecular Partners AG reinforced its key priority on contributing to the rapidly evolving field of immuno-oncology as the DARPin platform is ideally suited to develop differentiated immuno-oncology therapies with the potential to overcome some of the limitations of first-generation approaches. The company announced initial strategies of its proprietary immuno-oncology pipeline, including two multi-DARPin programs which are evaluating new principles that were previously difficult to achieve.

Financial Outlook 2016

Molecular Partners reiterates all elements of the financial outlook 2016 as provided in the company’s 2015 full-year results on February 4, 2016.

For the full year 2016, at constant exchange rates, the company expects total expenses of CHF 50-60 million, of which around CHF 6 million will be non-cash effective costs for share-based payments, IFRS pension accounting and depreciations. However, this may change substantially depending on the progress of the pipeline, mainly driven by the speed of enrollment of patients in clinical trials and data from research and development projects. Additionally, the company expects around CHF 3 million of capital expenditures, mainly for laboratory equipment.

No guidance can be provided with regard to net cash flow projections. Timelines and potential milestone payments for existing and potentially new partnerships cannot be disclosed.

Financial Calendar 2016

Publication of Half-year Results 2016

September 1, 2016

Publication of Quarterly Management Statement Q3 2016

October 27, 2016

http://investors.molecularpartners.com/financial-calendar-and-events/

 

About Molecular Partners AG

Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new, class of therapies known as DARPins. DARPins are potent, specific, and versatile small-protein therapies, which have the potential to offer benefits over conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin technology has the potential to offer a multi-specific approach to treatment, which enables DARPins to target multiple pathways, or multiple epitopes on a single target to achieve substantial patient benefit. DARPins have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders.

Molecular Partners has four compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company has ongoing research and development partnerships with leading pharmaceutical companies, including Allergan and Janssen, and is backed by established biotech investors. For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.

For further details, please contact:

Dr. Christian Zahnd, CEO
christian.zahnd@molecularpartners.com
Tel: +41 (0) 44 755 77 00

Andreas Emmenegger, CFO
andreas.emmenegger@molecularpartners.com
Tel: +41 (0) 44 755 77 00

Rolf Schläpfer
Hirzel.Neef.Schmid.Counselors
rolf.schlaepfer@konsulenten.ch
Tel: +41 (0) 43 344 42 42

 

Disclaimer

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Molecular Partners AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.

Shareholders of Molecular Partners AG approved all Board proposals at the Annual General Meeting – Jeffrey H. Buchalter elected new Board member

Zurich-Schlieren, April 20, 2016. At today’s Annual General Meeting of Molecular Partners AG (ticker: MOLN SW), the shareholders of the company approved all motions proposed by the Board of Directors with a large majority and elected Jeffrey H. Buchalter as new member of the Board of Directors of the company.

At today’s Annual General Assembly of Molecular Partners AG, Jeffrey H. Buchalter was elected as new member of the Board of Directors. Mr. Buchalter served in various senior executive positions, including being CEO of NASDAQ-listed Enzon (NASDAQ:ENZN) and of Ilex Oncology, as well as a Senior Executive at Pharmacia, Wyeth and Schering-Plough. He also brings experience from serving as chairman and non-executive director on various boards. He will replace Dr. Francesco De Rubertis who decided not to stand for re-election.

Jörn Aldag, Chairman of Molecular Partners commented: “We are very pleased to welcome Jeff as a new member of our Board. With his many years of strategic and operational experience in the life science industry with a focus in the commercial positioning and development of therapeutics in oncology, he will add a critical expertise to our Board.”

Jörn Aldag, Goran Ando, Steven H. Holtzman, William A. Lee, Andreas Plückthun, Petri Vainio and Christian Zahnd were all re-elected as members of the Board of Directors, and Jörn Aldag was also re-elected as Chairman of the Board of Directors of Molecular Partners AG. The proposed three members of the Compensation Committee – Jörn Aldag, William A. Lee and Petri Vainio – were also re-elected.

Further, the shareholders of Molecular Partners AG approved the annual report and the annual financial statements for the financial year 2015, as well as the appropriation of the 2015 results. The Board of Directors and the Management Board were granted discharge for the financial year 2015.

The shareholders of the company also approved the renewal of the authorized share capital for another period of two years and all proposals regarding compensation, including the proposed respective compensation amounts for the Board of Directors and the Management Board.

Financial Calendar 2016

Publication of Half-year Results 2016

September 1, 2016

Publication of Quarterly Management Statement Q3 2016

October 27, 2016

http://investors.molecularpartners.com/financial-calendar-and-events/

 

About Molecular Partners AG

Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new, class of therapies known as DARPins. DARPins are potent, specific, and versatile small-protein therapies, which have the potential to offer benefits over conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin technology has the potential to offer a multi-specific approach to treatment, which enables DARPins to target multiple pathways, or multiple epitopes on a single target to achieve substantial patient benefit. DARPins have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders.

Molecular Partners has four compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company has ongoing research and development partnerships with leading pharmaceutical companies, including Allergan and Janssen, and is backed by established biotech investors. For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.

 

For further details, please contact:

Dr. Christian Zahnd, CEO
christian.zahnd@molecularpartners.com
Tel: +41 (0) 44 755 77 00

Andreas Emmenegger, CFO
andreas.emmenegger@molecularpartners.com
Tel: +41 (0) 44 755 77 00

Rolf Schläpfer
Hirzel.Neef.Schmid.Counselors
rolf.schlaepfer@konsulenten.ch
Tel: +41 (0) 43 344 42 42

 

Disclaimer

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Molecular Partners AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.

Molecular Partners AG announces successful completion of placement of shares

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY,
IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN

Zurich-Schlieren, April 14, 2016. Molecular Partners AG (ticker: MOLN SW),a clinical‐stage biopharmaceutical
company that is developing a new class of therapies known as DARPins today announced the successful completion of a selldown of shares.

Certain shareholders of Molecular Partners AG, including employees, consultants, members of the board of directors of Molecular Partners AG and certain venture capital shareholders have successfully placed 1,100,000 shares in an Accelerated Bookbuilding transaction. The shares have been priced at CHF 27.50 per share.

UBS AG is acting as Sole Global Coordinator and Joint Bookrunner, along with J.P. Morgan as Joint Bookrunner. Bank am Bellevue and Bank Vontobel are acting as Co-Lead Managers.

Financial Calendar 2016

Annual General Meeting of Molecular Partners AG April 20, 2016
Publication of Quarterly Management Statement Q1 2016 April 28, 2016
Publication of Half-year Results 2016 September 1, 2016
Publication of Quarterly Management Statement Q3 2016 October 27, 2016

http://investors.molecularpartners.com/financial-calendar-and-events/

About Molecular Partners AG

Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new, class of therapies known as DARPins. DARPins are potent, specific, and versatile small-protein therapies, which have the potential to offer benefits over conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin technology has the potential to offer a multi-specific approach to treatment, which enables DARPins to target multiple pathways, or multiple epitopes on a single target to achieve substantial patient benefit. DARPins have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders.

Molecular Partners has four compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company has ongoing research and development partnerships with leading pharmaceutical companies, including Allergan and Janssen, and is backed by established biotech investors. For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.

For further details, please contact:

Dr. Christian Zahnd, CEO
christian.zahnd@molecularpartners.com
Tel: +41 (0) 44 755 77 00

Andreas Emmenegger, CFO
andreas.emmenegger@molecularpartners.com
Tel: +41 (0) 44 755 77 00

Rolf Schläpfer
Hirzel.Neef.Schmid.Counselors
rolf.schlaepfer@konsulenten.ch
Tel: +41 (0) 43 344 42 42

Disclaimer

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Molecular Partners AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.

 

Important Cautionary Statement

This press release is not for distribution, directly or indirectly, in or into the United States of America. The shares that are subject of the private placement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or any U.S. state security laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act. There will be no public offer of the shares in the United States of America.

The shares that are the subject of the private placement are not being offered or sold to any person who is not a qualified investor in accordance with applicable securities laws, i.e. who does not fall under the exemptions under the rules set out in directive 2003/71 EC of the European Parliament and of the Council of 4 November 2003 on the Prospectus to be published when securities are offered to the public or admitted to trading (and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Member State of the European Economic Area that has implemented directive 2003/71 EC), including any relevant implementing measures in each Member State of the European Economic Area which has implemented said directives (collectively the “Prospectus Directive”).

This press release and the information contained herein are not, and under no circumstances are to be construed as, an advertisement or a public offering of securities or as a solicitation of an offer to buy securities in Canada or any province or territory thereof, Australia or Japan.

Molecular Partners AG upsizes the proposed placement to CHF 30,000,000 based on strong demand and a significant anchor order from a specialist US investor

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY,
IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN

Zurich-Schlieren, April 13, 2016. Molecular Partners AG (ticker: MOLN SW), a clinical-stage biopharmaceutical company that is developing a new class of therapies known as DARPins, today announced the launch of a selldown of shares. Based on significant demand and a large anchor order from a specialist US investor, the deal will now be upsized to a maximum aggregate sales price of approximately CHF 30,000,000. The vast majority of the incremental number of shares will be supplied by certain of the existing venture capital shareholders. All sellers will be subject to a 90 day lock-up.

The order book will close on April 14, 2016, 08.30am CET. The result of the transaction will be announced shortly afterwards.

UBS AG is acting as Sole Global Coordinator and Joint Bookrunner, along with J.P. Morgan as Joint Bookrunner. Bank am Bellevue and Bank Vontobel are acting as Co-Lead Managers.

Financial Calendar 2016

Annual General Meeting of Molecular Partners AG April 20, 2016
Publication of Quarterly Management Statement Q1 2016 April 28, 2016
Publication of Half-year Results 2016 September 1, 2016
Publication of Quarterly Management Statement Q3 2016 October 27, 2016

http://investors.molecularpartners.com/financial-calendar-and-events/

About Molecular Partners AG

Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new, class of therapies known as DARPins. DARPins are potent, specific, and versatile small-protein therapies, which have the potential to offer benefits over conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin technology has the potential to offer a multi-specific approach to treatment, which enables DARPins to target multiple pathways, or multiple epitopes on a single target to achieve substantial patient benefit. DARPins have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders.

Molecular Partners has four compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company has ongoing research and development partnerships with leading pharmaceutical companies, including Allergan and Janssen, and is backed by established biotech investors. For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.

For further details, please contact:

Dr. Christian Zahnd, CEO
christian.zahnd@molecularpartners.com
Tel: +41 (0) 44 755 77 00

Andreas Emmenegger, CFO
andreas.emmenegger@molecularpartners.com
Tel: +41 (0) 44 755 77 00

Rolf Schläpfer
Hirzel.Neef.Schmid.Counselors
rolf.schlaepfer@konsulenten.ch
Tel: +41 (0) 43 344 42 42

Disclaimer

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Molecular Partners AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.

 

Important Cautionary Statement

This press release is not for distribution, directly or indirectly, in or into the United States of America. The shares that are subject of the private placement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or any U.S. state security laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act. There will be no public offer of the shares in the United States of America.

The shares that are the subject of the private placement are not being offered or sold to any person who is not a qualified investor in accordance with applicable securities laws, i.e. who does not fall under the exemptions under the rules set out in directive 2003/71 EC of the European Parliament and of the Council of 4 November 2003 on the Prospectus to be published when securities are offered to the public or admitted to trading (and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Member State of the European Economic Area that has implemented directive 2003/71 EC), including any relevant implementing measures in each Member State of the European Economic Area which has implemented said directives (collectively the “Prospectus Directive”).

This press release and the information contained herein are not, and under no circumstances are to be construed as, an advertisement or a public offering of securities or as a solicitation of an offer to buy securities in Canada or any province or territory thereof, Australia or Japan.

Molecular Partners AG Announces Launch of Placement of Shares

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY,
IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN

Zurich-Schlieren, April 13, 2016. Molecular Partners AG (ticker: MOLN SW), a clinical-stage biopharmaceutical company that is developing a new class of therapies known as DARPins, today announced the launch of a selldown of shares by employees, certain consultants, and members of the board of directors of Molecular Partners AG via an accelerated bookbuilding.

During the first few years after incorporation, employees, consultants and members of the board of directors of Molecular Partners AG received stock options as an important part of their compensation packages in order to keep the cash burn at the lowest possible level. The first portion of these options is now approaching its expiration. Upon exercise, the respective option holders will be required to pay the corresponding income and wealth taxes as well as social security contributions.

Exercising option holders therefore intend to engage in a share placement in order to use the corresponding proceeds to cover these expenses. The option holders are planning to sell for this purpose a number of shares corresponding to a maximum aggregate sales price of approximately CHF 20,000,000. The settlement of the transaction is expected to take place on or around 18 April 2016. Molecular Partners AG and the option holders have agreed to a lock-up for 90 days from the closing date of the transaction.

At the occasion of the launch of this placement, a elements of the business and financial outlook 2016 have been confirmed by the Company  as provided with 2015 full-year results on 04 February 2016 as well as highlighted in the company’s Annual Report 2015 which was published on 17 March 2016.

UBS AG is acting as Sole Global Coordinator and Joint Bookrunner, along with J.P. Morgan as Joint Bookrunner. Bank am Bellevue and Bank Vontobel are acting as Co-Lead Managers.

Financial Calendar 2016

Annual General Meeting of Molecular Partners AG April 20, 2016
Publication of Quarterly Management Statement Q1 2016 April 28, 2016
Publication of Half-year Results 2016 September 1, 2016
Publication of Quarterly Management Statement Q3 2016 October 27, 2016

http://investors.molecularpartners.com/financial-calendar-and-events/

About Molecular Partners AG

Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new, class of therapies known as DARPins. DARPins are potent, specific, and versatile small-protein therapies, which have the potential to offer benefits over conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin technology has the potential to offer a multi-specific approach to treatment, which enables DARPins to target multiple pathways, or multiple epitopes on a single target to achieve substantial patient benefit. DARPins have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders.

Molecular Partners has four compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company has ongoing research and development partnerships with leading pharmaceutical companies, including Allergan and Janssen, and is backed by established biotech investors. For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.

 

For further details, please contact:

Dr. Christian Zahnd, CEO
christian.zahnd@molecularpartners.com
Tel: +41 (0) 44 755 77 00

Andreas Emmenegger, CFO
andreas.emmenegger@molecularpartners.com
Tel: +41 (0) 44 755 77 00

Rolf Schläpfer
Hirzel.Neef.Schmid.Counselors
rolf.schlaepfer@konsulenten.ch
Tel: +41 (0) 43 344 42 42

Disclaimer

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Molecular Partners AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.

 

Important Cautionary Statement

This press release is not for distribution, directly or indirectly, in or into the United States of America. The shares that are subject of the private placement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or any U.S. state security laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act. There will be no public offer of the shares in the United States of America.

The shares that are the subject of the private placement are not being offered or sold to any person who is not a qualified investor in accordance with applicable securities laws, i.e. who does not fall under the exemptions under the rules set out in directive 2003/71 EC of the European Parliament and of the Council of 4 November 2003 on the Prospectus to be published when securities are offered to the public or admitted to trading (and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Member State of the European Economic Area that has implemented directive 2003/71 EC), including any relevant implementing measures in each Member State of the European Economic Area which has implemented said directives (collectively the “Prospectus Directive”).

This press release and the information contained herein are not, and under no circumstances are to be construed as, an advertisement or a public offering of securities or as a solicitation of an offer to buy securities in Canada or any province or territory thereof, Australia or Japan.